MRK Merck & Co., Inc.

Mentions (87)

• Newszacks.com·4d ago·Neutral

  Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

  View source ↗
• Newsbusinesswire.com·5d ago·Neutral

  Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29.

  View source ↗
• Newszacks.com·5d ago·Neutral

  Why Merck (MRK) Dipped More Than Broader Market Today In the latest trading session, Merck (MRK) closed at $145.31, marking a -2.66% move from the previous day.

  View source ↗
• Newsbenzinga.com·5d ago·Neutral

  Merck Says Investigational Skin Therapy Shows Potential Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EADV) 2026 Congress.

  View source ↗
• Newszacks.com·6d ago·Neutral

  Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation.

  View source ↗
• News247wallst.com·6d ago·Positive

  Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire math.

  View source ↗
• News (RSS)scmp·7d ago·Negative

  AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso

  View source ↗
• Newszacks.com·7d ago·Neutral

  FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.

  View source ↗
• Newsreuters.com·8d ago·Negative

  Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Merck said on Monday it would pay up to $2.13 billion under a ​global licensing deal with China's SciBrunch Therapeutics ‌for rights to develop, manufacture and sell an experimental cancer treatment.

  View source ↗
• Newsglobenewswire.com·8d ago·Neutral

  Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for Leadership Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets. com's offering. The global magnetic beads market was valued at an estimated US$3. 3 billion in 2025 and is projected to reach US$7

  View source ↗
• Newsglobenewswire.com·8d ago·Neutral

  Global Grignard Reagents Market Outlook and Forecast, 2026–2032 - Market to Reach USD 7.87 Billion as Safer, AI-Enabled Production Expands Opportunities for Merck KGaA, Thermo Fisher Scientific, and Tokyo Chemical Industry Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Grignard Reagents Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets. com's offering. The Grignard Reagents Market research report provides a comprehensive assessment of industry growth, production trends, appli

  View source ↗
• Newsbusinesswire.com·10d ago·Neutral

  …awn RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions …

  View source ↗
• Newszacks.com·10d ago·Neutral

  Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

  View source ↗
• Newsbusinesswire.com·11d ago·Neutral

  U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC).

  View source ↗
• News (RSS)thestreet·11d ago·Negative

  Bank of America has strong message for Merck stock investors A private meeting with the drugmaker's top doctor points to the next make-or-break moment for shareholders.

  View source ↗
• Newsreuters.com·12d ago·Negative

  Merck's eye disease drug meets main goal in trial Merck said ​on Thursday ‌its drug met ​the main ​goal in a ⁠mid- ​to late-stage ​trial testing it in ​adult ​patients with a ‌type ⁠of disease that affects blood ​vessels ​at ⁠the back ​of ​the ⁠eye.

  View source ↗
• Newszacks.com·12d ago·Neutral

  Merck (MRK) Declines More Than Market: Some Information for Investors In the latest trading session, Merck (MRK) closed at $148.08, marking a -1.88% move from the previous day.

  View source ↗
• Newsproactiveinvestors.com·12d ago·Positive

  Merck pipeline seen driving potential re-rating as clinical catalysts approach Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with Merck chief medical officer Eliav Barr, who conveyed confidence in the company's pipeline, with oncology and other programs providing mu…

  View source ↗
• News (RSS)seekingalpha·13d ago·Neutral

  Merck says FDA approved label update for PAH therapy Winrevair

  View source ↗
• Newszacks.com·13d ago·Neutral

  Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

  View source ↗
• Newsbusinesswire.com·14d ago·Negative

  …rial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signaling inhibitor, is FDA-approved for the …

  View source ↗
• Newszacks.com·14d ago·Neutral

  Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.

  View source ↗
• Newsbusinesswire.com·15d ago·Negative

  …a-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therap…

  View source ↗
• News (Marketaux)finance.yahoo.com·16d ago·Positive

  Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story? Quick Read Amgen (AMGN) yields 2.6% wit[+291 characters]

  View source ↗
• Newsbusinesswire.com·18d ago·Neutral

  …ev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuv…

  View source ↗
• Newszacks.com·18d ago·Positive

  Merck (MRK) Outperforms Broader Market: What You Need to Know Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day.

  View source ↗
• Newsmarketbeat.com·21d ago·Neutral

  Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation Merck & Co., Inc. NYSE: MRK Chairman and CEO Rob Davis said the company's “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its Animal Health segment during a Morgan Stanley discussion.

  View source ↗
• Newsseekingalpha.com·21d ago·Positive

  Merck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Merck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• News (RSS)investing·21d ago·Neutral

  Perspective Therapeutics partners with Merck on cancer trial

  View source ↗
• Newsglobenewswire.com·22d ago·Neutral

  …utical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.

  View source ↗
• News (RSS)yahoo·23d ago·Neutral

  Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock

  View source ↗
• Newsyoutube.com·23d ago·Neutral

  REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine Tempus CEO Eric Lefkofsky discusses the company's artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #tempus #ericlefkofsky #lefkofsky #merck #ai #artificialintelligence #healthcare #precisionmedicine #medicine #medicalresearch #technology #clinicaldata #patientcare #healtht

  View source ↗
• Newszacks.com·24d ago·Negative

  MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.

  View source ↗
• Newsbenzinga.com·25d ago·Neutral

  Congresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions Retail investors often monitor the trading activity of members of Congress. Investors may want to pay particular attention to recent trades from one member, with stocks connected to Elon Musk and Warren Buffett among the bets.

  View source ↗
• Newszacks.com·25d ago·Neutral

  Merck (MRK) Dips More Than Broader Market: What You Should Know In the most recent trading session, Merck (MRK) closed at $144.71, indicating a -1.91% shift from the previous trading day.

  View source ↗
• Newszacks.com·26d ago·Neutral

  Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

  View source ↗
• Newsmarketbeat.com·26d ago·Negative

  Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss Merck & Co., Inc. NYSE: MRK executives outlined a strategy centered on pipeline investment, new product launches and targeted business development as the company prepares for the eventual loss of exclusivity for KEYTRUDA.

  View source ↗
• News (RSS)seekingalpha·26d ago·Positive

  Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  View source ↗
• Newsseekingalpha.com·26d ago·Positive

  Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  View source ↗
• Newszacks.com·28d ago·Neutral

  Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell? MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.

  View source ↗
• News (RSS)coindesk·28d ago·Neutral

  Tracking cocoa may be just the beginning for PwC, Merck, Hashgraph provenance system The firms say their combination of physical authentication, digital traceability and enterprise process design has no precedent in supply chains, and cocoa is just the start.

  View source ↗
• Newszacks.com·31d ago·Neutral

  Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.

  View source ↗
• Newszacks.com·32d ago·Neutral

  Why Is Merck (MRK) Up 18.2% Since Last Earnings Report? Merck (MRK) reported earnings 30 days ago. What's next for the stock?

  View source ↗
• Newsreuters.com·32d ago·Negative

  India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar India's Cipla said on Thursday its U.S. unit entered an ​exclusive partnership with China's Qilu Pharmaceutical ‌to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. ​market.

  View source ↗
• News (RSS)investing·35d ago·Positive

  HSBC upgrades Merck KGaA to Buy on attractive valuation; shares climb

  View source ↗
• 4chan /biz/biz·36d ago·Neutral

  Opinions on Moonlake therapeutics? Merck once tried to acquire them for 3 billion, but they rejected it because it was too low. They are currently worth 1.2 billion and, as far as I can see, their pipeline hasn't really changed and the drug has been performing as well as the other best in class drug.

  View source ↗
• News (RSS)yahoo·37d ago·Positive

  Healthcare’s Best Week Since June Traces Back to a Single Moderna and Merck Cancer Trial

  View source ↗
• News (RSS)yahoo·38d ago·Neutral

  Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial

  View source ↗
• News (Marketaux)finance.yahoo.com·38d ago·Neutral

  Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets. Two that stand out today in the healthca[+278 characters]

  View source ↗
• News (RSS)fool·38d ago·Positive

  Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets. Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

  View source ↗
• Newszacks.com·40d ago·Positive

  Merck Stock Hits New 52-Week High: What's Driving the Rally? MRK hits a 52-week high as positive melanoma data, pipeline progress, new launches and M&A bolster its long-term growth outlook.

  View source ↗
• News247wallst.com·41d ago·Negative

  Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200? The setup around Merck (NYSE:MRK | MRK Price Prediction) shares heading into September is unusual for a mega-cap pharma.

  View source ↗
• News (RSS)yahoo·41d ago·Neutral

  Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

  View source ↗
• News (Marketaux)finance.yahoo.com·41d ago·Positive

  Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned. On August 19, 2026, Merck ([+323 characters]

  View source ↗
• News (RSS)thestreet·42d ago·Negative

  A cancer vaccine years in the making just proved itself Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.

  View source ↗
• News (RSS)seekingalpha·43d ago·Neutral

  Notable healthcare headlines for the week: Moderna, Merck, and Twist Bioscience in focus

  View source ↗
• News (RSS)seekingalpha·44d ago·Positive

  Notable analyst calls this week: Apple, Merck and Analog Devices among top picks

  View source ↗
• Newsforbes.com·45d ago·Positive

  Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma? This article was written by Doug Nathman, with research by his team at Trefis.

  View source ↗
• News (RSS)channelnewsasia·45d ago·Positive

  CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available and why researchers hope the approach can be used against other cancers.

  View source ↗
• Newszacks.com·45d ago·Negative

  Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE? MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.

  View source ↗
• News (RSS)seekingalpha·46d ago·Neutral

  SA analyst upgrades/downgrades: AVGO, MRK, HPE, WULF

  View source ↗
• News (RSS)seekingalpha·46d ago·Positive

  Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades

  View source ↗
• News (Finnhub)CNBC·46d ago·Negative

  Jim Cramer's top 10 things to watch in the stock market Thursday Walmart is selling off on disappointing earnings, and analysts are divided on Merck after its cancer vaccine breakthrough.

  View source ↗
• News (RSS)zerohedge·46d ago·Neutral

  …ng-end yields, and S&P 500 futures saw a clear move higher following the US Treasury’s announcement. On top of that, there were huge gains for Moderna (+176.97%) and Merck & Co. (+12.60%) after they announced successful trial results for a skin cancer vaccine, which led the S&P 500 healthcare sector (+3.52%) to its best day since April 2025. In fact, US equities would have seen an even stronger performance were it not for a fresh decline in chip stocks, with the Philly semiconductor index (-2.12…

  View source ↗
• Newszacks.com·46d ago·Neutral

  MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.

  View source ↗
• News (RSS)barrons·46d ago·Neutral

  Health Care Roundup: Market Talk Find insight on Ebos, Moderna, Merck and more in the latest Market Talks covering the health care sector.

  View source ↗
• News (RSS)investing·47d ago·Negative

  Merck KGaA shares fall after UBS downgrades stock to Neutral

  View source ↗
• News (RSS)investing·47d ago·Neutral

  Why is Merck stock sliding today?

  View source ↗
• 4chan /biz/biz·47d ago·Neutral

  >>62611128 Not gonna say which big pharma i work at but careful because investors are very forward thinking and the mcap factors in a lot more than the basics. Investing is more akin to sportsbetting that constantly changes throughout the game but in this case it's prospective drug patents guaranteeing future income. Also Moderna has employee counts in the thousands, 10x smaller than their peers. To give another example this is a joint venture with Merck who's shareprice is now at all time despi

  View source ↗
• News (RSS)japantimes·47d ago·Negative

  Moderna, Merck breakthrough could usher in wave of cancer vaccines The treatment involves pairing Merck's immunotherapy drug with a customized mRNA vaccine that instructs the immune system to attack specific cancer cells.

  View source ↗
• News (RSS)aljazeera·47d ago·Negative

  Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.

  View source ↗
• News (RSS)barrons·47d ago·Positive

  Bond Yields Dive After Treasury Increases Buybacks Plus, Moderna and Merck surge on mRNA cancer vaccine results.

  View source ↗
• News (RSS)seekingalpha·47d ago·Neutral

  Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead

  View source ↗
• News (RSS)seekingalpha·47d ago·Negative

  Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade)

  View source ↗
• News (RSS)livemint·47d ago·Neutral

  US stocks bounce back as bond yields retreat, Moderna rallies over 150%, Merck jumps 9.6% As of 10:30 a.m. Eastern Time, the S&P 500 rose 0.4%, the Dow Jones Industrial Average was up 0.5%, and the Nasdaq Composite was virtually unchanged.

  View source ↗
• News (RSS)ft·47d ago·Negative

  Moderna shares soar over 150% on melanoma vaccine trial success Drugmaker’s cancer shot developed with Merck delivers positive outcome in late-stage trial

  View source ↗
• News (RSS)livemint·47d ago·Negative

  Moderna shares climb over 110% as mRNA vaccine with Merck succeeds in large trial for skin cancer The study is still ongoing, but interim results showed that the treatment, Intismeran, met its primary endpoint of reducing the risk of cancer recurrence

  View source ↗
• News (RSS)zerohedge·47d ago·Neutral

  … much as 100% after the company and Merck said their personalized cancer vaccine helped cut the recurrence of melanoma in a large, late-stage trial. Shares of Merck (MRK) are up 8%. Norfolk Southern Corp. (NSC) rises 2% as the company and Union Pacific Corp. can move forward with plans to create the nation’s first coast-to-coast freight network after a federal regulator decided to resume consideration of their joint application. SK Hynix ADRs (SKHY) rise 3% after the South Korean memory-chip mak…

  View source ↗
• Newsseekingalpha.com·47d ago·Positive

  Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade) Merck & Co., Inc. has outperformed, surging 72% since my last bullish call versus the benchmark's 15%. MRK now trades at 14x 15-month forward P/E, but lofty FY2027 earnings expectations limit margin for error. I've downgraded MRK from Strong Buy to Hold, preferring to wait for fundamentals to catch up.

  View source ↗
• News (RSS)zerohedge·47d ago·Neutral

  …te-Stage Trial Success Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company. The study met its primary endpoint by showing that the cancer vaccine, called intismeran autogene, combined with Merck's blockbuster immunotherapy Keytr…

  View source ↗
• News (RSS)investing·47d ago·Neutral

  Why is Merck stock surging today?

  View source ↗
• News (RSS)zerohedge·48d ago·Neutral

  Vaccine-Maker Claims Splitting MMR Shot Could Take Up To 10 Years Vaccine-Maker Claims Splitting MMR Shot Could Take Up To 10 Years Authored by Zachary Stieber via The Epoch Times, Splitting the measles, mumps, rubella (MMR) vaccine into separate shots could take up to a decade, according to one of the two companies that produce the vaccine for the U.S. market. A tray of MMR vaccine vials at a clinic in Lubbock, Texas, on March 1, 2025. Jan Sonnenmair/Getty Images "Even under current expedited r

  View source ↗
• News (RSS)seekingalpha·50d ago·Neutral

  Notable healthcare headlines for the week: Eli Lilly, Hims & Hers Health, and Merck in focus

  View source ↗
• Newszacks.com·53d ago·Neutral

  Can Keytruda Sustain Merck's Growth in the Second Half of 2026? MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.

  View source ↗
• 4chan /biz/biz·54d ago·Positive

  Do you know about the HALO trade? Heavy Assets Low Obsolescence HALO It's become basically the counter AI trade. HALO companies are companies with high capital costs, and heavy assets. And big moats. Like a manufacturing company, like Ford or some s***, or Walmart. It's had a low correlation with the AI trade. There's some new HALO etfs, but they have like 70 bps fees or some s***. I'll show you a HALO ETF with dirt cheap fees. SCHD. It's not a perfect HALO tracker but it's like 90% there. A

  View source ↗
• Newszacks.com·55d ago·Neutral

  MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell? Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.

  View source ↗
• News (RSS)cnbc·62d ago·Negative

  Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.

  View source ↗